UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 3, 2009
Synergy Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Florida |
|
333-131722 |
|
20-3823853 |
(State or other jurisdiction |
|
(Commission |
|
IRS Employer |
of incorporation or organization) |
|
File Number) |
|
Identification No.) |
420 Lexington Avenue, Suite 1609
New York, NY 10170
(Address of principal executive offices)
Registrants telephone number, including area code: (212) 297-0020
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 7.01 Regulation FD Disclosure.
On June 3, 2009, Synergy Pharmaceuticals, Inc. (the Company) presented clinical data from a Phase I healthy volunteer study of SP-304, a new member of a class of investigational drugs for the treatment of constipation-predominant irritable bowel syndrome (IBS-C), and chronic idiopathic constipation, at the Digestive Disease Week annual meeting. The Companys presentation is furnished as Exhibit 99.1 to this report. The Company is also filing as Exhibit 99.2 to this Current Report on Form 8-K, an investor presentation it intends to present to various investors from time to time.
The information disclosed under this Item 7.01, including Exhibits 99.1 and 99.2 hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), nor shall it be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, (the Securities Act) except as expressly set forth in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
99.1 Synergy Pharmaceuticals, Inc. Presentation of SP-304 Phase I Clinical Data.
99.2 Synergy Pharmaceuticals, Inc. Investor Presentation
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: June 3, 2009
|
SYNERGY PHARMACEUTICALS, INC. |
|
|
|
|
|
|
|
|
By: |
/s/ Gary S. Jacob |
|
|
Gary S. Jacob, Ph.D. |
|
|
President and Acting Chief Executive Officer |
3